Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions
A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions in Chinese Participants Undergoing Allergy Testing
This multicenter, open-label, Phase III interventional study will evaluate the diagnostic performance and safety of ragweed pollen and dog dander skin prick test (SPT) solutions in adults in China with current or previous allergic diseases. Participants will undergo serum allergen-specific immunoglobulin E (sIgE) testing using the Thermo Fisher Scientific ImmunoCAP system. Each enrolled participant will receive one skin prick with ragweed pollen solution (3,500 DU/mL), dog dander solution (19,500 DU/mL), dog dander solution (39,000 DU/mL), and positive and negative controls. Wheal responses will be assessed 15-20 minutes after skin pricking. Diagnostic sensitivity and specificity will be determined separately for each test solution against the corresponding serum sIgE classification (cutoff ≥0.70 kUA/L). Safety will be assessed through adverse events, symptoms, vital signs, physical examinations, and laboratory tests.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Wang Jiazheng
- Telefonnummer: +8615800536923
- E-Mail: wangjiazheng@wolwobiotech.com
Studienorte
-
-
-
Beijing, China, 100730
- Beijing Tongren Hospital, Capital Medical University
-
Kontakt:
- Zhang Luo
- Telefonnummer: +861065141136
- E-Mail: dr.luozhang@139.com
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Tongji Hospital, Tongji Medical College of Hust
-
Kontakt:
- Zhu Rongfei
- Telefonnummer: +862783662912
- E-Mail: Zrf13092@163.com
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030032
- Shanxi Bethune Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female participants aged 18-60 years, inclusive.
- Participants with a current or previous history of allergic diseases, such as allergic rhinitis, allergic conjunctivitis, or allergic asthma.
- Participants who are able to understand the study and voluntarily provide written informed consent.
Exclusion Criteria:
- History of needle-related syncope or vasovagal reactions to the sight of blood.
- Pregnant or breastfeeding women.
- History of malignant tumors.
- Currently receiving beta-blockers or angiotensin-converting enzyme inhibitors and unable to discontinue treatment during the study.
- Currently experiencing a severe allergic reaction or having a history of severe allergic reactions, including generalized urticaria, severe or more serious acute asthma exacerbations, or anaphylactic shock.
- Use of topical corticosteroids or topical calcineurin inhibitors at the intended skin prick site within 7 days before SPT.
- Systemic use of antihistamines or antihistamine-containing combination medications before SPT, with a discontinuation period not exceeding five elimination half-lives of the antihistamine.
- Use of short-acting systemic corticosteroids within 2 days, intermediate-acting systemic corticosteroids within 5 days, or long-acting systemic corticosteroids within 12 days before SPT.
- Systemic use of immunosuppressants within 14 days before SPT.
- Use of phenothiazine antipsychotics within 10 days or imipramine-class antidepressants within 21 days before SPT.
- Treatment with dupilumab or similar agents within 3 months before SPT.
- Treatment with omalizumab or similar agents within 5 months before SPT.
- Photochemotherapy on the volar surfaces of both forearms within 30 days before SPT.
- Skin infection, dermatitis, trauma, scarring, pigmentation, or other pathological changes at the intended volar forearm test site that, in the investigator's judgment, may interfere with SPT interpretation.
- Positive skin scratch test for dermographism during screening.
- Participation in another drug clinical trial with administration of an investigational product within 1 month before screening, or less than five elimination half-lives since the last administration of that investigational product, whichever period is longer.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Skin Prick Test Group
All enrolled participants receive ragweed pollen SPT solution (3,500 DU/mL), dog dander SPT solution (19,500 DU/mL), dog dander SPT solution (39,000 DU/mL), and positive and negative control solutions during the same test session. |
One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later. One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later. One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Sensitivity: Ragweed Pollen (3,500 DU/mL)
Zeitfenster: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a positive SPT result among participants with serum ragweed sIgE ≥0.70 kUA/L by ImmunoCAP (w1). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Specificity: Ragweed Pollen (3,500 DU/mL)
Zeitfenster: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a negative SPT result among participants with serum ragweed sIgE <0.70 kUA/L by ImmunoCAP (w1). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Sensitivity: Dog Dander (19,500 DU/mL)
Zeitfenster: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Specificity: Dog Dander (19,500 DU/mL)
Zeitfenster: 15-20 minutes after skin prick testing (Day 1).
|
Measure Description: Percentage of participants with a negative SPT result among participants with serum dog dander sIgE <0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Sensitivity: Dog Dander (39,000 DU/mL)
Zeitfenster: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Specificity: Dog Dander (39,000 DU/mL)
Zeitfenster: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a negative SPT result among participants with serum dog dander sIgE <0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Adverse Events
Zeitfenster: From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.
|
Number and percentage of participants experiencing adverse events, adverse drug reactions, serious adverse events, serious adverse drug reactions, and adverse events leading to withdrawal, by test solution as applicable. |
From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.
|
|
Changes in Vital Signs from Baseline
Zeitfenster: At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.
|
Changes in vital signs from baseline will be assessed, including body temperature (°C), systolic and diastolic blood pressure (mmHg), and pulse rate (beats/min). Descriptive statistics, including mean, median, standard deviation, quartiles, minimum, and maximum, will be presented.Changes in vital signs will be summarized using cross-tabulations. Clinically significant abnormalities will be listed. |
At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.
|
|
Changes in Physical Examination Findings from Baseline
Zeitfenster: At screening and on Day 2 of the study or at early termination.
|
Changes in physical examination findings from baseline will be assessed, including skin and mucosa, lymph nodes, head and neck, chest, abdomen, and spine and extremities. Changes in examination findings will be summarized using cross-tabulations. Clinically significant abnormalities will be listed. |
At screening and on Day 2 of the study or at early termination.
|
|
Changes in Hematology Parameters from Baseline
Zeitfenster: At screening and on Day 2 of the study or at early termination.
|
Changes in hematology parameters from baseline will be assessed, including white blood cell count; absolute and percentage counts of neutrophils, lymphocytes, monocytes, eosinophils, and basophils; red blood cell count; hemoglobin; and platelet count. Units of measurement will follow the laboratory reports. Quantitative results will be summarized using the mean, median, standard deviation, quartiles, minimum, and maximum. Changes in clinical assessment categories will be summarized using cross-tabulations. Clinically significant abnormalities will be listed. |
At screening and on Day 2 of the study or at early termination.
|
|
Changes in Urinalysis Parameters from Baseline
Zeitfenster: At screening and on Day 2 of the study or at early termination.
|
Changes in urinalysis parameters from baseline will be assessed, including urine bilirubin, glucose, ketones, protein, occult blood, and leukocytes or leukocyte esterase. Results will be summarized according to the categories reported by the laboratory. Changes in results will be summarized using cross-tabulations. Clinically significant abnormalities will be listed. |
At screening and on Day 2 of the study or at early termination.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- WOLWO-D1-0III32-1
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .